RECURRENT BURKITT LYMPHOMA
Clinical trials for RECURRENT BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for aggressive lymphomas
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Apr 01, 2026 20:11 UTC
-
New drug duo aims to tame resistant blood cancers
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Three-Pronged attack tested against tough blood cancer
Disease control TerminatedThis study aimed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could help control an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to standard treatments. The trial was designed …
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC